Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?

  • Olivier Rascol
  • Published 1999 in Journal of neural transmission. Supplementum

Abstract

Three new dopamine agonists (cabergoline, pramipexole, ropinirole) have been put on to the market within the past months to treat patients with Parkinson's disease. Like any marketed dopamine agonists, the new compounds bind to the D2-like receptors. Pramipexole and ropinirole appear to be quite close drugs. Both are selective non ergot D2 (and… (More)

Topics

Cite this paper

@article{Rascol1999DopamineAW, title={Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?}, author={Olivier Rascol}, journal={Journal of neural transmission. Supplementum}, year={1999}, volume={55}, pages={33-45} }